Importantly, tocilizumab (a monoclonal IL-6 receptor antibody) has been approved for treating SSc-ILD and a study has found that serum SPP1 levels decrease following tocilizumab treatment in SSc-ILD patients. This evidence concerns the gene SPP1 and interstitial lung disease.